Browse > Article

AWARENESS OF KOREAN DENTISTS ON BISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAWS : PRELIMINARY REPORT  

Park, Yong-Duck (Department of Preventive and Public Health Dentistry, School of Medicine, Kyung Hee University)
Kim, Young-Ran (Department of Oral & Maxillofacial Surgery, School of Dentistry, School of Medicine, Kyung Hee University)
Kim, Deog-Yoon (Department of Nuclear Medicine, School of Medicine, Kyung Hee University)
Chung, Yoon-Sok (Department of Endocrinology, Ajuo University School of Medicine)
Lee, Jeung-Keun (Department of Dentistry, Ajuo University School of Medicine)
Kim, Yeo-Gab (Department of Oral & Maxillofacial Surgery, School of Dentistry, School of Medicine, Kyung Hee University)
Kwon, Yong-Dae (Department of Oral & Maxillofacial Surgery, School of Dentistry, School of Medicine, Kyung Hee University)
Publication Information
Journal of the Korean Association of Oral and Maxillofacial Surgeons / v.35, no.3, 2009 , pp. 153-157 More about this Journal
Abstract
Recently, an increasing number of bisphosphonate related osteonecrosis of the jaw(BRONJ) is being reported. A guideline has been already established in the US, but it does not seem to be fully recognized by clinicians in Korea. Therefore, a survey study was done to inform and have clinicians realize the seriousness of BRONJ. 1,341 practitioners were randomly selected out of 13,405 practitioners(by Feb of 2008, KDA) in Korea. A questionnaire was given to them between May to July in 2008. Questions were designed to investigate each respondent's experience term years in the clinic, occupation, speciality, awareness on risk of bisphosphonate, experience on treating osteonecrosis patients, awareness about the guideline on BRONJ suggested by AAOMS and whether if they ask about bisphosphonate medication history to patients before invasive treatment. 45.1% of the clinicians have reported on experiencing delayed healing on bone exposed site after extraction both in the maxilla and the mandible. However, clinicians have asked the patients whether if they are on bisphosphonate or not in only 15.1% of these cases. 56.5% of the clinicians simply knew about BRONJ but only 28.9% of the clinicians were aware that bisphosphonate can cause osteonecrosis after invasive dental treatment. Only 19.3% knew about the contents of guideline on BRONJ and 57.2% were aware of the seriousness of BRONJ. Clinicians with shorter clinical experience term were more aware of BRONJ and the guideline on BRONJ than the experienced clinicians. But awareness of the possibility of BRONJ after invasive dental treatment were about the same regardless of their clinical experience. The results show that Korean clinicians need to be more aware about BRONJ. Data on BRONJ cases in Korea should be collected and provided with additional education to let Korean clinicians know and be more aware about BRONJ.
Keywords
Bisphosphonate; Osteonecrosis; ONJ;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 국민건강보험공단 2007통계연보, 대한민국, 2008
2 Bize R, Lamy O, Peytremann-Bridevaux I. Osteoporotic fracture in menopausal women: alendronate reduces the risk. Rev MedSuisse. 2008 Dec 10;4:2703
3 American Association of Oral & Maxillofacial Surgeons. 2006 position paper on Bisphosphonate-related osteonecrosis of the jaw. Available at http://www.aamos.org/2006
4 Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JAet al. Once-yearly zoledronic acid for treatment of postmenopausalosteoporosis. N Eng1 J Med 2007;356:1809-22   DOI   ScienceOn
5 Altundag K, Bulut N, Tezcan E, Ozen M, Purnak T. Tooth extraction: Is it inciting event or sequela of osteonecrosis of the jaws associated with intravenous bisphosphonates? J OralMaxillofac Surg 2007;65:154   DOI   ScienceOn
6 Groetz KA, Al-Nawas B. Persisting alveolar sockets-a radiologic symptom of BP-ONJ. J Oral Maxillofac Surg 2006;64:1571-2   DOI   ScienceOn
7 http://www.nso.go.kr/
8 Bagan JV, Murillo J, Jimenez Y. Avascular jaw osteonecrosis inassociation with cancer chemotherapy : series of 10 cases. J OralPathol Med 2005;34:120-3   DOI   ScienceOn
9 Hansen T, Kunkel M, Weber A, James Kirkpatrick C.Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis.J Oral Pathol Med 2006;35:155-60   DOI   ScienceOn
10 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) inducedavascular necrosis of the jaw : a growing epidemic. J OralMaxillofac Surg 2003;61:1115-7   DOI   ScienceOn
11 Haderslev KV, Tjellesen L, Sorensen HA et al. Alendronate increaseslumbar spine bone mineral density in patients withCrohn's disease. Gastroenterology 2000;119:639-46   DOI   ScienceOn
12 Ruggiero SL. Mehrotra B. Rosenberg TJ. Osteonecrosis of thejaws associated with the use of bisphosphonates : a review of 63cases. J Oral Maxillofac Surg 2004;62:527-34   DOI   ScienceOn
13 Grotz KA. Zahnarztliche Betreuung von Patienten mit tumortherapeutischerKopf-Hals-Bestrahlung (Stellungnahme der DGZMKund DEGRO). Dtsch Zahnrztl Z. 2002;57:509
14 National Osteoporosis Foundation. American's Bone Health. Available at http://nof.org/advocacy/prevalence/index.htm
15 Schilling J. Management of bisphosphonate-induced osteonecrosis of the jaw. Northwest Dent. 2008;87:34-5,37-8, 40   PUBMED   ScienceOn
16 Walter C, Grotz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonateassociated osteonecrosis of the jaw within the fieldof osteonecrosis. Support Care Cancer 2007;15:197-202   DOI   ScienceOn
17 Dimitrakopoulos I. Magopoulos C, Karakasis D. Bisphos-phonateinducedavascular osteonecrosis of the jaws: a clinical report of 11cases. Int J Oral Maxillofac Surg 2006;35:588-93   DOI   ScienceOn
18 Kwon YD, Yoon BW, Walter C. Bisphosphonate, is it an emergingrisk factor in oral surgery? J Korean Assoc Maxillofac PlastReconstr Surg 2007;29:456-62